Safety and efficacy of the combination of pegylated interferon-alpha 2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients
2016 (English)In: Leukemia, ISSN 0887-6924, E-ISSN 1476-5551, Vol. 30, no 9, 1853-1860 p.Article in journal (Refereed) Published
Dasatinib (DAS) and interferon-a have antileukemic and immunostimulatory effects and induce deep responses in chronic myeloid leukemia (CML). We assigned 40 newly diagnosed chronic-phase CML patients to receive DAS 100 mg o.d. followed by addition of pegylated interferon-alpha 2b (PegIFN) after 3 months (M3). The starting dose of PegIFN was 15 mu g/week and it increased to 25 mu g/week at M6 until M15. The combination was well tolerated with manageable toxicity. Of the patients, 84% remained on PegIFN at M12 and 91% (DAS) and 73% (PegIFN) of assigned dose was given. Only one patient had a pleural effusion during first year, and three more during the second year. After introduction of PegIFN we observed a steep increase in response rates. Major molecular response was achieved in 10%, 57%, 84% and 89% of patients at M3, M6, M12 and M18, respectively. At M12, MR4 was achieved by 46% and MR4.5 by 27% of patients. No patients progressed to advanced phase. In conclusion, the combination treatment appeared safe with very promising efficacy. A randomized comparison of DAS +/- PegIFN is warranted.
Place, publisher, year, edition, pages
NATURE PUBLISHING GROUP , 2016. Vol. 30, no 9, 1853-1860 p.
IdentifiersURN: urn:nbn:se:liu:diva-132071DOI: 10.1038/leu.2016.121ISI: 000383786400003PubMedID: 27133821OAI: oai:DiVA.org:liu-132071DiVA: diva2:1038424
Funding Agencies|Bristol-Myers Squibb; Norwegian University of Science and Technology (NTNU, Trondheim, Norway)2016-10-182016-10-172016-10-18